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Abstract: Leishmania (Mundinia) martiniquensis is a causative agent of visceral leishmaniasis, but in
HIV-infected patients both visceral and disseminated cutaneous leishmaniasis are presented.
Recurrence of the disease after treatment has been reported in some cases indicating that improved
chemotherapy is required. In this study, the susceptibility of L. martiniquensis to Amphotericin
B deoxycholate (AmB), allicin, and andrographolide was evaluated and the synergistic effects of
allicin or andrographolide combined with AmB against L. martiniquensis intracellular amastigotes
in mouse peritoneal exudate macrophages (PEMs) were investigated in vitro for the first time.
The results showed that L. martiniquensis was highly susceptible to AmB as expected, but allicin
and andrographolide had selectivity index (SI) values greater than 10, indicating promise in both
compounds for treatment of host cells infected with L. martiniquensis. Four AmB/allicin combinations
presented combination index (CI) values less than 1 (0.58–0.68) for intracellular amastigotes indicating
synergistic effects. The combination with the highest dose reduction index (DRI) allowed an
approximately four-fold reduction of AmB use in that combination. No synergistic effects were
observed in AmB/andrographolide combinations. The data provided in this study leads for further
study to develop novel therapeutic agents and improve the treatment outcome for leishmaniasis
caused by this Leishmania species.
Keywords:Leishmaniamartiniquensis;Mundinia; Amphotericin B deoxycholate; allicin; andrographolide;
synergistic effect; drug combination
1. Introduction
Leishmaniasis is an emerging disease in Thailand and South East Asia, in which most of the human
cases to date have presented with the clinical features of disseminated and/or visceral leishmaniasis
accompanied by HIV infection [1,2]. The number of clinically and parasitologically confirmed cases
remains relatively small (about 25), however, the appearance of leishmaniasis in South East Asia has
raised important concerns for two reasons. The first concern is that clinical disease may become more
Pathogens 2020, 9, 49; doi:10.3390/pathogens9010049 www.mdpi.com/journal/pathogens
Pathogens 2020, 9, 49 2 of 13
widely established in the region than appears to be the case at present. For example, in the adjacent
region of South Asia visceral leishmaniasis is a major public health challenge [3]. The second concern
is the suspicion that there is already a much higher underlying rate of infection than current numbers
suggest, for example, in a recent study a prevalence of 25.1% was indicated in HIV patients in southern
Thailand [4].
Leishmania (Mundinia) martiniquensis is the most frequent cause of leishmaniasis in Thailand [1,2].
The parasite was first isolated in 1995 on the island of Martinique [5] and fully described in 2014 [6]. This
new species has been placed in a new subgenus L. (Mundinia) [7] and studied relatively little. In Thailand,
Pothirat et al. (2014) reported the first case of autochthonous visceral leishmaniasis in northern Thailand
and the aetiological agent was identified as L. martiniquensis [8]. In South East Asia L. martiniquensis can
present in a range of clinical presentations, most frequently as visceral leishmaniasis in patients with
no known underlying immunodeficiency [8]. However, when accompanied by HIV-infection, both
visceral and/or disseminated cutaneous leishmaniasis has been reported [9], similar to elsewhere [10].
Amphotericin B deoxycholate (AmB), a sterol-complexing agent, is the only first-line drug currently
available in Thailand and has been used to treat most of the cases [1]. However, the susceptibility
of L. martiniquensis to AmB has not been previously investigated and recurrence of the disease after
treatment has occurred in some cases, in both seronegative and immunocompromised patients including
HIV-infected patients, indicating that improved chemotherapy is required [1,11]. Disadvantages of
current therapy with AmB include low solubility leading to poor bioavailability, renal toxicity, other
occasional serious side effects, the need for administration by slow infusion, and infusion-associated
reactions such as thrombophlebitis, chills, and high fever with rigor [12]. Moreover, the requirement
for long periods of parenteral administration, frequently requiring hospitalization, has limited the
clinical use of AmB [13]. Unfortunately, the less toxic liposomal formulation of AmB, Ambisome®,
is not available in Thailand, and, therefore, new drugs or more effective combinations are required.
The use of combinations of different drugs and/or compounds may also bring significant advantages
and better therapeutic effects than each of the substances alone.
Allicin and andrographolide are readily available natural products that have shown promise as
antileishmanial agents. Allicin has been reported to be effective against the intracellular stages of
L. donovani and L. infantum without substantial cytotoxicity for mammalian cells [14,15], and against
the in vitro growth of L. mexicana and L. infantum promastigotes [16]. Allicin works with AmB against
intracellular amastigotes of L. donovani and L. infantumwith a moderate synergistic effect with a two-fold
reduction of AmB [15]. It has also shown inhibition of the growth of L. major promastigotes [17].
In addition, Corral et al. (2016) have reported that allicin causes necrotic death in L. infantum [17].
Another interesting compound, andrographolide, has shown strong general antileishmanial effects
against L. donovani-infected macrophages in vivo [18]. It has also been reported to have antiplasmodial
activity against Plasmodium falciparum erythrocytic stages [19] and antitrypanosomal activity against
Trypanosoma brucei [20]. Neither allicin nor andrographolide have been tested for their effects on
L. martiniquensis.
The aims of this study were to evaluate the susceptibility of L. martiniquensis to AmB, allicin, and
andrographolide, followed by the investigation of any synergistic effects of allicin or andrographolide
combined with AmB against L. martiniquensis intracellular amastigotes in mouse peritoneal exudate
macrophages (PEMs). The results provided by this study give crucial baseline information on the
efficacy of the current first-line treatment for leishmaniasis in Thailand and South East Asia, and
also enable assessment of potential improvements to the treatment regime using a combination
chemotherapy approach.
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2. Results
2.1. Antileishmanial Activity against Promastigotes
Exposure of L. martiniquensis promastigotes to AmB, allicin, and andrographolide demonstrated
that the drug and both compounds were able to inhibit parasite growth. The half maximal
inhibitory concentration (IC50) values of allicin and andrographolide were 7.70 (7.69–7.71) µg/mL
and 4.04 (4.03–4.05) µg/mL, respectively. The IC50 value of AmB was 0.040 (0.039–0.041) µg/mL,
showing the L. martiniquensis promastigotes were much more sensitive to AmB than either allicin or
andrographolide alone.
2.2. Cytotoxicity on BALB/c Peritoneal Macrophages
The cytotoxicity of AmB, allicin, and andrographolide on mouse PEMs was determined because
these are mammalian cells, but also because they were used as the host cells for L. martiniquensis
infection assays. The 50% cytotoxic concentration (CC50) values for AmB, allicin, and andrographolide
were 54.0 (47.2–60.8), 13.9 (13.4–14.4), and 6.60 (6.03–7.17) µg/mL, respectively. These results show that
andrographolide was the most toxic of the three, although overall there were not large differences in
their effects on PEMs.
2.3. Antileishmanial Activity against Intracellular Amastigotes
Although the efficacy of potential drugs against Leishmania promastigotes is useful information,
as an intracellular parasite it is essential that any drug is able to access the amastigote forms of the
parasite inside their host cells, as well as displaying selective toxicity for the parasites within. The activity
of compounds against amastigote forms of L. martiniquensis was determined in Leishmania-infected
macrophages. The microscopic observations of Giemsa-stained cells demonstrated that the drug and
both compounds had effects on intracellular parasites. Untreated control showed numerous amastigotes
in macrophages (Figure 1A). AmB reduced the number of intracellular amastigotes at 0.02 µg/mL
(Figure 1B), and macrophages were free of parasites after treatment with AmB at 0.63 µg/mL (Figure 1C).
Allicin was less effective than AmB but was able to reduce intracellular amastigotes at 0.63 µg/mL
and no intracellular amastigotes were found after treatment with 10 µg/mL of allicin (Figure 1D,E).
Similarly, andrographolide was able to reduce intracellular amastigotes at 0.31 µg/mL and no parasites
were observed after treatment with 10 µg/mL of andrographolide (Figure 1F,G). AmB drug and both
compounds reduced the infection index in a dose-dependent manner. The IC50 values for allicin and
andrographolide were 0.59 (0.49–0.69) µg/mL and 0.45 (0.35–0.55) µg/mL, respectively, whereas the
IC50 value of AmB was 0.0152 (0.0147–0.0157) µg/mL. These results are in broad agreement with those
obtained with promastigotes. To compare their selective toxicity, the selectivity index (SI) values
(CC50/IC50) were calculated. The SI values were 23.55, 14.66, and 3553 for allicin, andrographolide, and
AmB, respectively, confirming that AmB was the most effective of the three compounds.
2.4. Activity of Synergistic Combinations against Intracellular Amastigotes
The possible synergistic effects of allicin or andrographolide when combined with AmB against
intracellular amastigotes was investigated by using the Chou-Talalay combination index method.
Allicin and andrographolide at 0.64 µg/mL and AmB at 0.01 µg/mL provided an approximate 50%
growth inhibition, which were similar to previous IC50 results. The percentage of infected macrophages
after 48 h of incubation with no treatment (untreated control) was in a range of 50–60% (data not shown).
The percentage of growth inhibition (compared with untreated control) obtained from the checkerboard
method was used to determine combination index (CI) value of each combination in order to identify
the type of interaction (synergism, addition, or antagonism). An interaction between AmB and allicin
was found from synergism with the lowest concentration of AmB used (0.0025 µg/mL) plus allicin
(0.16 µg/mL) to moderate antagonism with the highest concentration of AmB used (0.01 µg/mL) plus
allicin (0.64 µg/mL). However, four combinations of AmB/allicin (0.0025:0.16, 0.0025:0.32, 0.005:0.16, and
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0.005:0.32 µg/mL) were classified as synergism and one combination (0.01:0.16 µg/mL) was classified
as nearly additive (Table 1). Similarly, a graphical representation (isobologram) representing AmB and
allicin interactions indicates synergy for four combinations by showing four data points below the line
of additivity (Figure 2). Combinations of AmB/allicin with synergistic effects allowed dose reductions
for a given effect level. The combination of AmB 0.0025 µg/mL plus allicin 0.32 µg/mL showed the
highest dose reduction index (DRI) with approximately a four-fold reduction of AmB use, as shown in
Table 1. No cytotoxicity assay on macrophages was performed for those combinations with synergism
effect as the combinations used lower concentration of drug/compound than the drug or compound
alone and no host cell damage was observed.Pathogens 2020, 9, x FOR PEER REVIEW 4 of 14 
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Table 1. Effects of AmB, allicin, and their combinations on intracellular amastigotes of L. martiniquensis
in peritoneal exudate macrophages (PEMs).
Drug Combination
Non-Constant Ratio (µg/mL) 1 % Growth
Inhibition 2 CI
3 Interaction
Dose Reduction
Index (DRI) 4
AmB Allicin AmB Allicin
0 0 0
0.0025 25.98 (22.7–29.3)
0.005 37.79 (32–43.6)
0.01 52.76 (51.3–54.2)
0.16 32.28 (28.1–36.5)
0.32 41.73 (39.3–44.1)
0.64 51.18 (49.5–52.9)
0.0025 0.16 54.88 (50.6–59.2) *** 0.63 Synergism 3.02 3.39
0.0025 0.32 66.14 (62–70.3) *** 0.58 Synergism 4.29 2.90
0.0025 0.64 58.27 (56.6–60) *** 1.31 Moderate antagonism 3.34 0.99
0.005 0.16 64.56 (61.1–68.1) *** 0.68 Synergism 2.04 5.36
0.005 0.32 70.63 (65.9–75.4) *** 0.67 Synergism 2.50 3.67
0.005 0.64 60.87 (55–66.8) ** 1.44 Moderate antagonism 1.81 1.12
0.01 0.16 70.07 (67.6–72.6) ** 0.96 Nearly additive 1.23 7.12
0.01 0.32 66.93 (61.8–72) * 1.24 Moderate antagonism 1.10 3.02
0.01 0.64 69.92 (65.5–74.3) ** 1.39 Moderate antagonism 1.22 1.77
1 Concentration (µg/mL) of AmB combined with allicin. 2 % Growth inhibition (mean 95% confidence interval)
obtained from effect of AmB allicin alone, and their combinations. 3 CI (Combination index values analyzed
by CompuSyn software) classified as strong-to-very-strong synergism (CI < 0.3), synergism (CI = 0.3–0.7),
slight-to-moderate synergism (CI = 0.7–0.9), nearly additive (CI = 0.9–1.1), slight-to-moderate antagonism
(CI = 1.1–1.45), antagonism (CI = 1.45–3.3), and strong-to-very-strong antagonism (CI > 3.3). 4 Dose reduction index
(DRI) represents the fold of dose reduction allowed in a combination for a given degree of effect as compared
with the dose of each drug or compound alone. Statistical differences between the effects of AmB alone and the
combination of AmB plus allicin are indicated as follows: * p ≤ 0.01; ** p ≤ 0.001; *** p ≤ 0.0001.
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Figure 2. Representative normalized isobolograms of the interaction of AmB/allicin on L. martiniquensis
intracellular amastigotes. (A) 0.0025 µg/mL AmB plus 0.16 or 0.32 µg/mL allicin. (B) 0.005 µg/mL AmB
plus 0.16, 0.32, or 0.64 µg/mL allicin. (C) 0.01 µg/mL AmB plus 0.16, 0.32, 0.64, or 1.28 µg/mL allicin. Data
points (dots) located below, on, or above the line indicate synergy, additivity, or antagonism, respectively.
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An interaction of AmB and andrographolide was found from nearly additive to antagonism
(Table 2). Six out of twelve combinations of AmB/andrographolide showed additive effects on
intracellular parasites. The isobolograms for the interaction between AmB and andrographolide
demonstrate six data points located on the line of additivity indicating nearly additive effects (Figure 3).
Table 2. Effects of AmB, andrographolide, and their combinations on intracellular amastigotes of L.
martiniquensis in PEMs.
Drug Combination
Non-Constant Ratio (µg/mL) 1 % Growth
Inhibition 2 CI
3 Interaction
Dose Reduction
Index (DRI) 4
AmB Andrographolide AmB Andrographolide
0 0 0
0.0025 24.5 (21–28)
0.005 38.4 (32.3–44.5)
0.01 51.72 (48.8–54.7)
0.08 4.72 (2.68–6.76)
0.16 12.6 (9.88–15.3)
0.32 44.88 (38.7–51.1)
0.64 53.78 (50.7–56.8)
0.0025 0.08 31.5 (27.8–35.2) 0.93 Nearly additive 1.51 3.79
0.0025 0.16 37.8 (33.7–41.9) ** 0.98 Nearly additive 1.87 2.25
0.0025 0.32 51.18 (47.9–54.5) **** 0.98 Nearly additive 2.87 1.58
0.0025 0.64 59.05 (55.5–62.6) **** 1.31 Moderate antagonism 3.67 0.96
0.005 0.08 48.81 (43.8–53.8) * 0.92 Nearly additive 1.33 5.95
0.005 0.16 50.63 (44.8–56.5) * 1.03 Nearly additive 1.41 3.11
0.005 0.32 62.44 (60.3–64.6) *** 0.96 Nearly additive 2.05 2.10
0.005 0.64 51.18 (49–53.3) * 1.97 Antagonism 1.43 0.79
0.01 0.08 40.16 (37.1–43.2) ** 2.18 Antagonism 0.51 4.79
0.01 0.16 48.56 (46.1–51.1) 1.85 Antagonism 0.66 2.96
0.01 0.32 37.20 (30.8–43.7) *** 3.08 Antagonism 0.46 1.11
0.01 0.64 44.72 (39.9–49.6) * 3.19 Antagonism 0.58 0.67
1 Concentration (µg/mL) of AmB combined with andrographolide. 2 % Growth inhibition (mean 95% confidence
interval) obtained from effect of AmB, andrographolide alone, and their combinations. 3 CI (Combination index
values analyzed by CompuSyn software) classified as strong to very strong synergism (CI < 0.3), synergism
(CI = 0.3–0.7), slight to moderate synergism (CI = 0.7–0.9), nearly additive (CI = 0.9–1.1), slight to moderate
antagonism (CI = 1.1–1.45), antagonism (CI = 1.45–3.3), and strong to very strong antagonism (CI > 3.3). 4 Dose
reduction index (DRI) represents the fold of dose reduction allowed in a combination for a given degree of effect as
compared with the dose of each drug or compound alone. Statistical differences between the effects of AmB alone
and the combination of AmB plus andrographolide are indicated as follows: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001;
**** p ≤ 0.0001.
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3. Discussion
The action of AmB against L. martiniquensis was investigated in both promastigote and intracellular
amastigote assays, with IC50 values comparable to those seen with other Leishmania species [21,22].
Importantly, this confirms the logical use of AmB for chemotherapy of L. martiniquensis infection.
Although these parasites are found within a distinct subgenus, Leishmania (Mundinia), and are therefore
genetically distinct from other species of Leishmania, they must be sufficiently similar in terms of their
sterol composition for AmB to be an effective drug. With the goal of improving therapeutic applications
for L. martiniquensis infection by reduction of the undesirable side effects of AmB, we then evaluated
the susceptibility of L. martiniquensis to allicin and andrographolide, followed by investigation of the
synergistic effects of allicin or andrographolide combined with AmB against intracellular amastigotes
in PEMs. In the present study, allicin and andrographolide were able to act directly to inhibit the
growth of extracellular promastigotes of L. martiniquensis. Those antileishmanial activities were also
effective against intracellular amastigotes of L. martiniquensis in PEMs by showing SI values greater
than 10, which present promising results for the use of allicin and andrographolide for treatment of
host cells infected with L. martiniquensis [23,24].
To determine whether either compound was able to augment AmB monotherapy against
intracellular amastigotes in PEMs, combinations of allicin or andrographolide with AmB were
investigated for their efficacy. Our results showed that four AmB/allicin combinations demonstrated
synergistic effects, with the combination of 0.0025 µg/mL of AmB plus 0.32 µg/mL of allicin producing
the highest DRI, about a four-fold reduction of AmB used in the combination. Allicin has also
been reported to act synergistically with AmB against intracellular amastigotes of L. donovani and
L. infantum. The interaction of allicin and AmB against these Leishmania species was a moderate
synergistic effect with a two-fold reduction of AmB [15]. The combination of allicin and AmB was also
effective in other organisms, for example, An et al. (2009) found that allicin was able to enhance the
oxidative damage activity of AmB to destroy C. albicans [25]. Regarding mode of action in L. infantum
promastigotes, allicin alone directly interfered with calcium homeostasis and induced oxidative
stress leading to mitochondrial dysfunction [26]. Furthermore, previous studies have reported that
allicin reacted with thiols that caused a defect of trypanothione reductase in defense against reactive
oxygen species (ROS) [27,28]. Clearly, in our study allicin was able to diffuse and permeate across
cell membranes into macrophages, but the mechanism of allicin on intracellular amastigotes remains
unknown [29,30]. AmB effects Leishmania parasites by binding to ergosta-type sterols, these being
constituents of the plasma membrane, and then forming pores [31,32]. These results in leakage of
potassium ions leading to toxic effects through the absence of intracellular ionic substances, and also
induces ROS-based oxidative damage. Based on our findings, the synergistic effect of allicin with
AmB against intracellular amastigotes of L. martiniquensis, might be explained by enhancing the ability
of AmB to disrupt membrane function, as well as potential direct effects of allicin on trypanothione
reductase or mitochondrial function.
In the case of AmB and andrographolide combinations, no synergistic effect was observed in
any combination. Further, the AmB and andrographolide combinations were at best additive, but in
many cases showed strong antagonistic effects against intracellular amastigotes of L. martiniquensis.
In cancer cell therapy, andrographolide was able to work synergistically with anticancer agents to
inhibit the tumor growth by arresting cell cycle and inducing cell apoptosis [33–37]. So far, there are no
reports of synergistic effects of andrographolide in combination with AmB against any other Leishmania
species. In our study, andrographolide was able to inhibit growth of L. martiniquensis promastigotes
and affect intracellular amastigotes. Recently, nanoparticle formulations of andrographolide have
been used to target and treat L. donovani infected macrophages [38]. Furthermore, the successful
treatment of L. donovani-infected hamsters was achieved using the encapsulated andrographolide
in mannose-grafted liposomes [18]. Therefore, using carrier systems or new formulations might
improve the efficacy of AmB and andrographolide combinations. However, assessment of the effects
of the combinations in this present study should also be performed using an in vivo experimental
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model for L. martiniquensis, as some combinations that were effective in vitro might still act as useful
therapeutic partners.
In conclusion, in this study the susceptibility of L. martiniquensis to AmB, allicin, and
andrographolide was evaluated and the synergistic effects of allicin or andrographolide combined
with AmB against L. martiniquensis intracellular amastigotes in PEMs were investigated in vitro for
the first time. L. martiniquensis was susceptible to both allicin and andrographolide. However, only
allicin worked synergistically with AmB and reduced drug use in the combination against intracellular
amastigotes. These results might lead to further studies to improve the therapeutic outcome for the
Leishmania species.
4. Materials and Methods
4.1. Ethics Statement
All the protocols used for the care and use of laboratory animals were reviewed and approved
by the Ethics Committee on Animal Use of the Laboratory Animal Center, Chiang Mai University
(Protocol number 2561/MC-0008).
4.2. Parasites and Culture
L. martiniquensis (MHOM/TH/2013/LSCM3) originally isolated from a bone marrow sample of a
disseminated leishmaniasis patient [39] was used this study. For routine culture, promastigotes were
cultured in M199 medium (GE Healthcare Life Sciences, Logan, UT, USA), which was supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1% basal medium eagle vitamins (BME)
(Sigma-Aldrich, St. Louis, MO, USA), and 25 µg/mL gentamicin sulfate (Sigma-Aldrich, St. Louis, MO,
USA), pH 6.8 at 26 ◦C.
4.3. Drug and Compounds
Amphotericin B deoxycholate (250 µg/mL) was purchased from Gibco (Grand Island, NY, USA).
Allicin (liquid Allisure, 1000 ppm) was purchased from Allicin International Ltd. (Rye, East Sussex,
UK). Andrographolide (100 mg) was purchased from Sigma (St. Louis, MO, USA). A stock solution
of andrographolide (500 µg/mL) was prepared in dimethylsulfoxide (DMSO) and stored at −20 ◦C.
The final DMSO concentration (0.4%) had no effect on parasite growth in controls. Dilutions of AmB,
allicin, and andrographolide were prepared in the culture medium on the day of treatment and
immediately used.
4.4. Promastigote Assay
The antileishmanial activity of compounds against promastigotes was determined using
alamarBlue™ Cell Viability Reagent (Thermo Fisher Scientific, Waltham, MA, USA) as described by
the manufacturer with some modifications. Exponential phase promastigotes of L. martiniquensis
(2 × 106 cells/mL) prepared in M199 medium (supplemented with 10% FBS, 1% BME vitamins, and 25
µg/mL gentamicin sulfate) were plated in 96-well culture plates (Nunc, Roskilde, Denmark) (50µL/well).
The promastigotes then received 50 µL of medium alone (control) or containing different concentrations
of AmB (0.0025–0.32 µg/mL), allicin (0.63–40 µg/mL), or andrographolide (0.14–17.5 µg/mL), to obtain a
final volume of 100 µL, and incubated at 26 ◦C. After exposure to drug and compounds for 48 h, 10 µL
of alamarBlue™ Cell Viability Reagent was added to each well, and incubation continued for 24 h at
26 ◦C. Promastigote proliferation was determined using a plate reader (Synergy H4 Hybrid Microplate
reader, BioTek, Winooski, VT, USA) at wavelengths of 570 and 600 nm. Wells without cells and the
maximal concentration from each drug or compound and wells with culture medium and alamarBlue™
Cell Viability Reagent (10% v/v) were included as controls. The IC50 value, defined as the concentration
of drug or compound required to inhibit 50% promastigote growth, was determined from a sigmoidal
dose response curve generated using Graphpad prism 6 software (Graphpad software Inc., San Diego,
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CA, USA). These assays were performed in three independent experiments and in triplicate within
each experiment. Results are expressed as mean 95% confidence interval.
4.5. Cytotoxicity Assay
The use of mouse-derived PEMs can be advocated as an efficient, reliable, relatively quick, and
cost-effective tool for evaluation of antileishmanial drug or compound efficacy in vitro [40]. In this
study, PEMs were collected from female 8- to 12-week-old BALB/c mice (purchased from Nomura Siam
International Co., Ltd., Bangkok, Thailand) using the method described by Zhang et al. [41]. Trypan
blue (Sigma-Aldrich, St. Louis, MO, USA) was used to test for the initial viability of PEMs. The PEMs
were suspended in RPMI-1640 medium (GE Healthcare Life Sciences, Logan, UT, USA) (supplemented
with 10% FBS, 25 µg/mL gentamicin sulfate) and plated in 96-well culture plates (2.5 × 104 viable
cells/well; 100 µL/well) and incubated for 24 h at 37 ◦C, 5% CO2 to allow cell adherence. After that
the PEMs were incubated with their respective medium alone (control) or containing AmB, allicin,
or andrographolide at different concentrations (1.4–180 µg/mL) for 72 h at 37 ◦C, 5% CO2. Viability of
cells in presence of AmB, allicin, or andrographolide was determined using the alamarBlue™ assay.
Briefly, after 72 h of incubation, 10 µL of alamarBlue™ Cell Viability Reagent was added to each well
and incubation continued for 4 h at 37 ◦C, 5% CO2 before reading absorbance. Cell viability was
determined using a plate reader at wavelengths of 570 and 600 nm. Wells without cells and the maximal
concentration from each drug or compound and wells with culture medium and alamarBlue™ Cell
Viability Reagent (10% v/v) were included as controls. The CC50 value, defined as the concentration of
drug or compound required to induce 50% cell death, was determined from a sigmoidal dose response
curve using Graphpad prism 6 software (Graphpad Solfware Inc., San Diego, CA, USA). These assays
were performed in three independent experiments and in triplicate within each experiment. Results
are expressed as mean 95% confidence interval.
4.6. Preparation of Promastigotes to Infect Murine Macrophages
The preparation of promastigotes for infection in murine macrophages was performed as follows.
L. martiniquensis parasites derived from infected BALB/c mice (sixteen weeks post infection) were
used. The spleen of an infected mouse was removed aseptically and briefly placed in sterile phosphate
buffer saline. The spleen tissues were then minced in Schneider’s insect medium (SIM) (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10% FBS and 25 µg/mL gentamicin sulfate and strained using
a cell strainer (SPL Life Sciences Co., Ltd., Gyeonggi-do, Korea), using aseptic techniques. The resulting
opaque suspension was transferred to a 50 mL centrifuge tube (Nunc, Roskilde, Denmark), topped
up to 50 mL with SIM supplemented with 10% FBS, 25 µg/mL gentamicin sulfate, and centrifuged at
26 ◦C, 1500× g for 10 min. The supernatant medium was discarded. The pellet was resuspended in
SIM supplemented with 10% FBS, 25 µg/mL gentamicin sulfate, and incubated for 3 days at 26 ◦C to
allow promastigotes to grow. Such promastigotes were then subpassaged into RPMI-1640 medium
supplemented with 20% FBS, pH 5.5, 25 µg/mL gentamicin sulfate to stimulate growth followed by
metacyclogenesis [42] and incubated for 5 days at 26 ◦C. Stationary phase promastigote cultures with
>70% metacyclic promastigotes were used to infect PEMs.
4.7. Intracellular Amastigote Assay
To evaluate effect of drug or compounds alone on intracellular amastigotes of L. martiniquensis,
Leishmania-infected murine macrophages were prepared as follows. PEMs were collected from
BALB/c mice as described above, then suspended in RPMI-1640 medium supplemented with 10% FBS,
25 µg/mL gentamicin sulfate and plated in 8-well chamber slides (Nunc, Roskilde, Denmark) (5 ×
104 viable cells/well; 200 µL/well). Cultures were incubated for 24 h at 37 ◦C, 5% CO2 to allow cell
adherence. Adherent cells were infected with stationary phase promastigotes of L. martiniquensis in
RPMI-1640 medium supplemented with 2% FBS, 25 µg/mL gentamicin sulfate at a parasite/macrophage
ratio of 10:1 to achieve an optimal level of infection (approximate 90% infection) before starting
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drug sensitivity assay. Infected cells were washed to remove non-internalized promastigotes and
the medium replaced with RPMI-1640 medium supplemented with 2% FBS, 25 µg/mL gentamicin
sulfate containing different concentrations of AmB (0.002–0.63 µg/mL), allicin (0.04–10 µg/mL), and
andrographolide (0.04–10 µg/mL) and incubated for 48 h at 37 ◦C, 5% CO2. After the treatment,
infected macrophages were fixed with absolute methanol and stained with 5% Giemsa’s stain solution.
Intracellular amastigotes and infected macrophages were counted microscopically (from at least
300 macrophages). The infection index was calculated by multiplying the percentage of infected
macrophages by the average number of intracellular amastigotes per infected cells [43]. The IC50
value was determined from a sigmoidal dose response curve using Graphpad prism 6 software.
Results are expressed as mean 95% confidence interval of at least three independent experiments, each
performed in triplicate. The SI of the drug or compounds was calculated from the ratio of the CC50 for
macrophages and the IC50 for parasites.
4.8. Drug Combination Assay on Intracellular Amastigotes
Combination effects of drug and compounds against intracellular amastigotes were determined by
using checkerboard assays. AmB, allicin, and andrographolide at concentrations near or equal to their
IC50 values were prepared in double concentration and serially two-fold diluted in RPMI-1640 medium
supplemented with 2% FBS, 25 µg/mL gentamicin sulfate. Each compound with different dilutions
was combined with different dilutions of the drug. The matrix yielded 9 different combinations for
AmB/allicin and 12 different combinations for AmB/andrographolide. L. martiniquensis-infected murine
macrophages were prepared in 8-well chamber slides with a parasite/macrophage ratio of 10:1 as
described above. After 24 h of infection, infected macrophages were treated with compound alone
and in combinations with the drug for 48 h at 37 ◦C, 5% CO2. The slides were fixed with methanol
and stained with 5% Giemsa’s stain solution. Intracellular amastigotes of each treated group were
counted and calculated for percentage of growth inhibition compared to untreated control. Results are
expressed as mean 95% confidence interval of three experiments.
4.9. Analysis of Interaction
Interactions between compounds and the drug were determined based on the combined and
single antileishmanial activities. The nature of drug interactions was assessed using the Chou-Talalay
combination index method [44]. Each of the combinations combined with non-constant ratio was
analyzed using CompuSyn software (ComboSyn Inc., Paramus, NJ, USA). CI values were obtained
from non-linear regression results. The equation used was as follows:
CI =
CA,X
ICx,A
+
CB,X
ICx,B
CA,X and CB,X are the concentrations of drug A or drug B in the combination to produce X effect,
respectively; ICx,A and ICx,B are the concentrations of single drug A or drug B to produce the same
effect, respectively. CI value results provided a quantitative determination for strong-to-very-strong
synergism (CI < 0.3), synergism (CI = 0.3–0.7), slight-to-moderate synergism (CI = 0.7–0.9), nearly
additive (CI = 0.9–1.1), slight-to-moderate antagonism (CI = 1.1–1.45), antagonism (CI = 1.45–3.3) and
strong-to-very-strong antagonism (CI > 3.3). The DRI was also calculated, representing the fold of
dose reduction that is produced in combination for a given degree of effect, as compared with the
dose of each drug alone. Isobolograms were analyzed by using CompuSyn software (ComboSyn Inc.,
Paramus, NJ, USA) to illustrate a graphical presentation of two drug interactions. A point below, on,
or above the line of additivity indicates synergy, additivity, or antagonism, respectively.
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4.10. Statistical Analysis
Statistical analysis was performed using Excel (Microsoft, Microsoft Corporation, Redmond, WA,
USA), CompuSyn software (ComboSyn Inc., Paramus, NJ, USA), and Graphpad software (Graphpad
Solfware Inc., San Diego, CA, USA). Mean 95% confidence interval was calculated from triplicate
experiments. The statistical differences between groups were evaluated using one-way analysis of
variance (ANOVA), followed by the Bonferroni’s multiple comparison tests (using GraphPad prism
6 software (Graphpad Solfware Inc., San Diego, CA, USA)). Differences were considered significant
when p values were ≤ 0.05.
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